Profile data is unavailable for this security.
About the company
Neumora Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company’s therapeutic pipeline consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its advanced product candidate, navacaprant (NMRA-140), is a novel once-daily oral kappa opioid receptor (KOR) antagonist that is being developed for the treatment of depressive disorder (MDD). Its other candidates include NMRA-266, NMRA-511, and NMRA-NMDA. NMRA-266 is a positive allosteric modulator program of the M4 muscarinic receptor (M4R) for the treatment of schizophrenia. NMRA-266 is designed to be selective for the M4 receptor subtype of the muscarinic receptor family. NMRA-511 is an investigational antagonist of the vasopressin 1a receptor (V1aR). NMRA-NMDA is an NMDA positive allosteric modulator program that the Company is developing for the treatment of schizophrenia.
- Revenue in USD (TTM)0.00
- Net income in USD-254.02m
- Incorporated2019
- Employees120.00
- LocationNeumora Therapeutics Inc490 Arsenal Way, Suite 200WATERTOWN 02472United StatesUSA
- Phone+1 (857) 760-0900
- Fax+1 (302) 655-5049
- Websitehttps://neumoratx.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Veracyte Inc | 375.47m | -68.18m | 1.81bn | 815.00 | -- | 1.62 | -- | 4.83 | -0.9346 | -0.9346 | 5.12 | 14.64 | 0.3186 | 7.47 | 8.15 | 460,703.10 | -5.78 | -6.33 | -6.08 | -6.69 | 68.54 | 67.10 | -18.16 | -20.99 | 4.69 | -- | 0.00009 | -- | 21.76 | 31.45 | -103.51 | -- | 39.67 | -- |
Kiniksa Pharmaceuticals Ltd | 338.93m | -10.23m | 1.86bn | 297.00 | -- | -- | -- | 5.49 | -0.1788 | -0.1788 | 4.68 | -- | -- | -- | -- | 1,141,179.00 | -- | -16.49 | -- | -18.72 | 87.73 | -- | -3.02 | -53.64 | -- | -- | -- | -- | 22.74 | -- | -92.32 | -- | -52.35 | -- |
Keros Therapeutics Inc | 234.00k | -160.30m | 1.89bn | 141.00 | -- | 4.16 | -- | 8,067.99 | -5.14 | -5.14 | 0.0075 | 12.59 | 0.0005 | -- | -- | 1,720.59 | -36.84 | -35.95 | -38.35 | -38.07 | -- | -- | -68,505.13 | -1,237.26 | -- | -- | 0.00 | -- | -- | -56.77 | -46.15 | -- | 62.57 | -- |
Akero Therapeutics Inc | 0.00 | -179.27m | 1.94bn | 58.00 | -- | 2.30 | -- | -- | -3.20 | -3.20 | 0.00 | 12.24 | 0.00 | -- | -- | 0.00 | -28.43 | -37.73 | -29.53 | -40.13 | -- | -- | -- | -- | -- | -- | 0.0395 | -- | -- | -- | -35.46 | -- | -- | -- |
Vera Therapeutics Inc | 0.00 | -94.30m | 2.01bn | 55.00 | -- | 5.65 | -- | -- | -2.04 | -2.04 | 0.00 | 6.49 | 0.00 | -- | -- | 0.00 | -29.99 | -- | -31.92 | -- | -- | -- | -- | -- | -- | -- | 0.124 | -- | -- | -- | -7.79 | -- | -- | -- |
Arvinas Inc | 71.30m | -354.80m | 2.03bn | 445.00 | -- | 3.32 | -- | 28.46 | -6.05 | -6.05 | 1.22 | 8.93 | 0.0597 | -- | 12.08 | 160,224.70 | -29.59 | -22.01 | -37.90 | -26.47 | -- | -- | -495.65 | -316.55 | -- | -- | 0.0012 | -- | -40.26 | 40.53 | -30.02 | -- | 0.4852 | -- |
Mirum Pharmaceuticals Inc | 224.00m | -158.56m | 2.04bn | 278.00 | -- | 8.69 | -- | 9.12 | -3.82 | -3.82 | 5.19 | 4.99 | 0.4546 | 4.24 | 5.62 | 848,477.30 | -32.18 | -38.93 | -38.17 | -44.88 | 73.26 | -- | -70.79 | -190.71 | 3.47 | -- | 0.5667 | -- | 141.85 | -- | -20.45 | -- | 21.81 | -- |
Neumora Therapeutics Inc | 0.00 | -254.02m | 2.06bn | 120.00 | -- | 4.84 | -- | -- | -1.55 | -1.55 | 0.00 | 2.66 | 0.00 | -- | -- | 0.00 | -60.32 | -- | -63.83 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -80.23 | -- | -- | -- |
Syndax Pharmaceuticals Inc | 0.00 | -240.63m | 2.08bn | 112.00 | -- | 4.23 | -- | -- | -3.22 | -3.22 | 0.00 | 5.79 | 0.00 | -- | -- | 0.00 | -47.99 | -27.90 | -51.84 | -30.15 | -- | -- | -- | -324.34 | -- | -- | 0.00004 | -- | -- | -- | -40.19 | -- | -- | -- |
CG Oncology Inc | 539.00k | -72.33m | 2.20bn | 61.00 | -- | 3.87 | -- | 4,088.66 | -1.13 | -1.13 | 0.0084 | 8.54 | -- | -- | -- | 8,836.07 | -- | -- | -- | -- | -- | -- | -10,551.39 | -- | -- | -- | 0.00 | -- | 6.81 | -- | -54.83 | -- | -- | -- |
Structure Therapeutics Inc (ADR) | 0.00 | -97.68m | 2.20bn | 111.00 | -- | 4.19 | -- | -- | -2.32 | -2.32 | 0.00 | 9.22 | 0.00 | -- | -- | 0.00 | -27.73 | -- | -29.16 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -69.62 | -- | -- | -- |
Recursion Pharmaceuticals Inc | 46.24m | -354.11m | 2.28bn | 500.00 | -- | 4.94 | -- | 49.28 | -1.62 | -1.62 | 0.2112 | 1.69 | 0.078 | -- | 19.86 | 92,470.00 | -59.76 | -- | -69.49 | -- | 10.66 | -- | -765.90 | -- | -- | -- | 0.0028 | -- | 11.88 | -- | -36.99 | -- | -- | -- |
Janux Therapeutics Inc | 7.29m | -55.59m | 2.28bn | 64.00 | -- | 3.48 | -- | 313.01 | -1.22 | -1.22 | 0.159 | 12.65 | 0.014 | -- | 11.48 | 113,859.40 | -10.67 | -- | -10.95 | -- | -- | -- | -762.92 | -- | -- | -- | 0.00 | -- | -6.14 | -- | 7.56 | -- | -- | -- |
Rocket Pharmaceuticals Inc | 0.00 | -249.31m | 2.30bn | 268.00 | -- | 5.20 | -- | -- | -2.87 | -2.87 | 0.00 | 4.87 | 0.00 | -- | -- | 0.00 | -49.16 | -35.26 | -52.49 | -37.49 | -- | -- | -- | -- | -- | -- | 0.0458 | -- | -- | -- | -10.70 | -- | 62.52 | -- |
Maravai Lifesciences Holdings Inc | 274.10m | -131.04m | 2.31bn | 570.00 | -- | 5.62 | -- | 8.42 | -0.9917 | -0.9917 | 2.08 | 1.63 | 0.1458 | 2.93 | 5.90 | 421,690.80 | -8.49 | 12.67 | -11.29 | 15.46 | 44.03 | 74.79 | -58.27 | 37.32 | 10.47 | -2.02 | 0.4169 | 0.00 | -67.28 | 18.47 | -154.05 | -- | 78.56 | -- |
Holder | Shares | % Held |
---|---|---|
MIC Capital Management UK LLPas of 31 Mar 2024 | 4.46m | 2.80% |
T. Rowe Price Investment Management, Inc.as of 31 Mar 2024 | 3.58m | 2.25% |
ICONIQ Capital LLCas of 31 Mar 2024 | 3.40m | 2.13% |
Invus Public Equities Advisors LLCas of 31 Mar 2024 | 2.92m | 1.83% |
EcoR1 Capital, LLCas of 31 Mar 2024 | 2.07m | 1.30% |
Fidelity Management & Research Co. LLCas of 31 Mar 2024 | 1.86m | 1.17% |
Citadel Advisors LLCas of 31 Mar 2024 | 1.82m | 1.14% |
Avidity Partners Management LPas of 31 Mar 2024 | 1.80m | 1.13% |
Deep Track Capital LPas of 31 Mar 2024 | 1.00m | 0.63% |
BlackRock Fund Advisorsas of 31 Mar 2024 | 913.83k | 0.57% |